Thank you very much.
You recommended in chapter 4--in section 4.63, I believe--that the disclosure of information related to drug approvals be not only for drug approvals but also for rejections. The industry itself has always rejected that, claiming that it should not be forced to provide proprietary information on something that was actually rejected.
But the department, Health Canada, has actually agreed with your recommendation. How far should this go? There's a difference between just simply saying, “Yes, we agree, we should provide more information...”. What information really should be provided?